RecruitingPhase 2NCT06160232

Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder

Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Feasibility, Clinical Efficacy & (Neuro)Cognitive Mechanisms

Sponsor

Brugmann University Hospital

Enrollment

62 participants

Start Date

Feb 15, 2024

Study Type

INTERVENTIONAL

Conditions

Severe Alcohol Use Disorder

Summary

Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder: Protocol for a Double-Blind, Randomized, Placebo-Controlled, 7-month Parallel-Group Phase II Superiority Trial

Eligibility

Min Age: 21 YearsMax Age: 64 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Active placebo (low dose of psilocybin) and a drug called Psilocybin (high dose) for people with severe alcohol use disorder. The study is currently recruiting participants at 1 location. People eligible for this study include aged 21 Years to 64 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGPsilocybin (high dose)

Psilocybin-assisted therapy

DRUGActive placebo (low dose of psilocybin)

Placebo-assisted therapy

Locations(1)

Brugmann University Hospital

Brussels, Belgium

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06160232